(Q71181725)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678098%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

title

Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678098%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

author name string

W J Holloway

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678098%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

D Palmer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678098%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

publication date

1 June 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678098%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

16 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678098%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678098%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

issue

6A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678098%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

page(s)

52S-59S

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678098%20AND%20SRC:MED&resulttype=core&format=json

Urinary tract infections in women: diagnosis and treatment

16 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Pathophysiologic basis for the use of third-generation cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Major trends in the microbial etiology of nosocomial infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Gram-positive organisms and sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Cefepime: overview of activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Genetics of extended-spectrum beta-lactamases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

In-vitro activity of cefepime and other antimicrobials: survey of European isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

In-vitro antibacterial activity of cefepime: a multicentre study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. The Canadian Antimicrobial Resistance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Antibacterial activity of cefepime in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Low-dosage cefepime as treatment for serious bacterial infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

Epidemiology of Nosocomial Infections Due to Gram-Negative Bacilli: Aspects Relevant to Development and Use of Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900108-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(96)00108-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678098%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

1 reference